Clinical added value of MRI to CT in patients scheduled for local therapy of colorectal liver metastases (CAMINO): study protocol for an international multicentre prospective diagnostic accuracy study.
Abdominal CT scan
Colorectal cancer
Colorectal liver metastases
Diffusion weighted imaging
Gadoxetic acid
Hepatic resection
Liver MRI
Liver metastases
Liver surgery
Thermal ablation
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
18 Oct 2021
18 Oct 2021
Historique:
received:
15
07
2021
accepted:
04
10
2021
entrez:
19
10
2021
pubmed:
20
10
2021
medline:
29
1
2022
Statut:
epublish
Résumé
Abdominal computed tomography (CT) is the standard imaging method for patients with suspected colorectal liver metastases (CRLM) in the diagnostic workup for surgery or thermal ablation. Diffusion-weighted and gadoxetic-acid-enhanced magnetic resonance imaging (MRI) of the liver is increasingly used to improve the detection rate and characterization of liver lesions. MRI is superior in detection and characterization of CRLM as compared to CT. However, it is unknown how MRI actually impacts patient management. The primary aim of the CAMINO study is to evaluate whether MRI has sufficient clinical added value to be routinely added to CT in the staging of CRLM. The secondary objective is to identify subgroups who benefit the most from additional MRI. In this international multicentre prospective incremental diagnostic accuracy study, 298 patients with primary or recurrent CRLM scheduled for curative liver resection or thermal ablation based on CT staging will be enrolled from 17 centres across the Netherlands, Belgium, Norway, and Italy. All study participants will undergo CT and diffusion-weighted and gadoxetic-acid enhanced MRI prior to local therapy. The local multidisciplinary team will provide two local therapy plans: first, based on CT-staging and second, based on both CT and MRI. The primary outcome measure is the proportion of clinically significant CRLM (CS-CRLM) detected by MRI not visible on CT. CS-CRLM are defined as liver lesions leading to a change in local therapeutical management. If MRI detects new CRLM in segments which would have been resected in the original operative plan, these are not considered CS-CRLM. It is hypothesized that MRI will lead to the detection of CS-CRLM in ≥10% of patients which is considered the minimal clinically important difference. Furthermore, a prediction model will be developed using multivariable logistic regression modelling to evaluate the predictive value of patient, tumor and procedural variables on finding CS-CRLM on MRI. The CAMINO study will clarify the clinical added value of MRI to CT in patients with CRLM scheduled for local therapy. This study will provide the evidence required for the implementation of additional MRI in the routine work-up of patients with primary and recurrent CRLM for local therapy. The CAMINO study was registered in the Netherlands National Trial Register under number NL8039 on September 20th 2019.
Sections du résumé
BACKGROUND
BACKGROUND
Abdominal computed tomography (CT) is the standard imaging method for patients with suspected colorectal liver metastases (CRLM) in the diagnostic workup for surgery or thermal ablation. Diffusion-weighted and gadoxetic-acid-enhanced magnetic resonance imaging (MRI) of the liver is increasingly used to improve the detection rate and characterization of liver lesions. MRI is superior in detection and characterization of CRLM as compared to CT. However, it is unknown how MRI actually impacts patient management. The primary aim of the CAMINO study is to evaluate whether MRI has sufficient clinical added value to be routinely added to CT in the staging of CRLM. The secondary objective is to identify subgroups who benefit the most from additional MRI.
METHODS
METHODS
In this international multicentre prospective incremental diagnostic accuracy study, 298 patients with primary or recurrent CRLM scheduled for curative liver resection or thermal ablation based on CT staging will be enrolled from 17 centres across the Netherlands, Belgium, Norway, and Italy. All study participants will undergo CT and diffusion-weighted and gadoxetic-acid enhanced MRI prior to local therapy. The local multidisciplinary team will provide two local therapy plans: first, based on CT-staging and second, based on both CT and MRI. The primary outcome measure is the proportion of clinically significant CRLM (CS-CRLM) detected by MRI not visible on CT. CS-CRLM are defined as liver lesions leading to a change in local therapeutical management. If MRI detects new CRLM in segments which would have been resected in the original operative plan, these are not considered CS-CRLM. It is hypothesized that MRI will lead to the detection of CS-CRLM in ≥10% of patients which is considered the minimal clinically important difference. Furthermore, a prediction model will be developed using multivariable logistic regression modelling to evaluate the predictive value of patient, tumor and procedural variables on finding CS-CRLM on MRI.
DISCUSSION
CONCLUSIONS
The CAMINO study will clarify the clinical added value of MRI to CT in patients with CRLM scheduled for local therapy. This study will provide the evidence required for the implementation of additional MRI in the routine work-up of patients with primary and recurrent CRLM for local therapy.
TRIAL REGISTRATION
BACKGROUND
The CAMINO study was registered in the Netherlands National Trial Register under number NL8039 on September 20th 2019.
Identifiants
pubmed: 34663243
doi: 10.1186/s12885-021-08833-1
pii: 10.1186/s12885-021-08833-1
pmc: PMC8524830
doi:
Substances chimiques
Contrast Media
0
gadolinium ethoxybenzyl DTPA
0
Gadolinium DTPA
K2I13DR72L
Types de publication
Clinical Trial Protocol
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1116Subventions
Organisme : kwf kankerbestrijding
ID : 11916 / 2018-2
Investigateurs
C Bnà
(C)
C De Meyere
(C)
W A Draaisma
(WA)
M F Gerhards
(MF)
F Imani
(F)
K F D Kuhlmann
(KFD)
M S L Liem
(MSL)
Y Meyer
(Y)
J S D Mieog
(JSD)
G P Serafino
(GP)
H C Van Beek
(HC)
J A B Van der Hoeven
(JAB)
C J Veeken
(CJ)
Informations de copyright
© 2021. The Author(s).
Références
Br J Surg. 2014 May;101(6):613-21
pubmed: 24652690
Cancer Treat Rev. 2015 Nov;41(9):729-41
pubmed: 26417845
Jpn J Radiol. 2012 Oct;30(8):648-58
pubmed: 22836904
Int J Colorectal Dis. 2016 Nov;31(11):1739-1749
pubmed: 27682648
J Magn Reson Imaging. 2018 May;47(5):1237-1250
pubmed: 28901685
Radiology. 2003 Jun;227(3):752-7
pubmed: 12773679
Cancer Epidemiol. 2015 Oct;39(5):734-44
pubmed: 26277328
J Surg Oncol. 2014 Nov;110(6):734-8
pubmed: 24965163
Sci Data. 2019 Mar 19;6(1):6
pubmed: 30890711
Acta Radiol. 2016 Sep;57(9):1040-8
pubmed: 26622057
Int J Hepatol. 2013;2013:572307
pubmed: 23653860
Diagn Interv Imaging. 2014 May;95(5):505-12
pubmed: 24794793
J Magn Reson Imaging. 2010 Jan;31(1):19-31
pubmed: 20027569
Clin Exp Metastasis. 2015 Jun;32(5):457-65
pubmed: 25899064
JAMA Surg. 2013 Jul;148(7):597-601
pubmed: 23699996
Magn Reson Med Sci. 2007;6(1):43-52
pubmed: 17510541
J Nucl Med. 2009 Jul;50(7):1036-41
pubmed: 19525451
J Surg Oncol. 2019 Sep;120(3):438-445
pubmed: 31168858
BMC Med Imaging. 2018 Nov 15;18(1):44
pubmed: 30442100
Wien Klin Wochenschr. 2018 Nov;130(21-22):665-672
pubmed: 30167887
Radiology. 2010 Dec;257(3):674-84
pubmed: 20829538
BMJ. 2013 Jan 08;346:e7586
pubmed: 23303884
Eur J Surg Oncol. 2004 Apr;30(3):286-91
pubmed: 15028310
JAMA. 2014 May 14;311(18):1863-9
pubmed: 24825641
BMC Cancer. 2015 May 06;15:365
pubmed: 25943574
Dig Surg. 2008;25(6):445-60
pubmed: 19212117
J Am Coll Radiol. 2017 May;14(5S):S234-S244
pubmed: 28473079
HPB (Oxford). 2017 Nov;19(11):992-1000
pubmed: 28760631
Abdom Imaging. 2012 Feb;37(1):74-82
pubmed: 21597893
BMJ Open. 2016 Nov 14;6(11):e012799
pubmed: 28137831
Br J Surg. 2016 Jul;103(8):1055-62
pubmed: 27193207
Ann Surg. 2014 Nov;260(5):822-7; discussion 827-8
pubmed: 25379853
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
Cancer. 2007 Feb 15;109(4):718-26
pubmed: 17238180
Radiology. 2005 Oct;237(1):123-31
pubmed: 16100087
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593